BTL's new laser division enters crowded resurfacing market with first fused-wavelength erbium platform.
BTL has established a dedicated laser division and introduced EXOLASE ONE, marketed as the first fused-erbium laser combining multiple erbium wavelengths in a single handpiece. The platform targets full-body resurfacing—face, neck, décolletage, hands—with the pitch that fused wavelengths reduce treatment time and improve efficacy versus single-wavelength systems.
The competitive landscape for erbium is already dense. Cutera's Pearl and Pearl Fractional, Sciton's MOXI, Cynosure's PicoWay, and DEKA's ONDA systems all own significant market share in the fractional-resurfacing space. BTL's entry hinges on whether the fused-wavelength approach delivers measurable clinical or economic advantage—faster treatment cycles, fewer passes, better results—that justifies switching costs for practices already invested in existing platforms.
Fused-wavelength approach must deliver measurable advantage to justify switching costs.
The timing aligns with growing demand for non-invasive full-body skin treatments, especially among GLP-1 users managing skin laxity post-weight loss. If EXOLASE ONE's economics and clinical outcomes prove competitive, it could carve space. If not, it joins a graveyard of me-too laser platforms that couldn't justify the capital outlay.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
